share_log

Piper Sandler Initiates Coverage On Orchestra BioMed Hldgs With Overweight Rating, Announces Price Target of $15

Piper Sandler Initiates Coverage On Orchestra BioMed Hldgs With Overweight Rating, Announces Price Target of $15

吹笛者桑德勒啟動對樂團 BioMed 控股超重評級的報導,宣布目標價格為 15 美元
Benzinga ·  2023/02/24 08:53

Piper Sandler analyst Matt O'Brien initiates coverage on Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight rating and announces Price Target of $15.

Piper Sandler分析師馬特·奧布萊恩對樂團BioMed Hldgs(納斯達克:OBIO)進行了增持評級,並宣佈目標價為15美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論